Patents Assigned to Merck
  • Patent number: 10651382
    Abstract: The present invention relates to a formulation containing at least one organic functional material and at least a first and a second solvent, characterized in that the first solvent is a siloxane.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Patent GmbH
    Inventors: Gaëlle Béalle, Christoph Leonhard, Hsin-Rong Tseng, Irina Martynova, Aurélie Ludemann
  • Patent number: 10647727
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregori J. Morriello, Lehua Chang, Ashley Forster, Richard Berger, Kausik K. Nanda, William D. Shipe
  • Patent number: 10647861
    Abstract: Alpha-Alumina flakes having a particle thickness of 130-400 nm, a D50-value of 15-30 ?m, a D90-value of 30-45 ?m and a D10-value of <9.5 ?m. Use of the alumina flakes in varnishes, paints, automotive coatings printing inks, masterbatches, plastics and cosmetic formulations. Also, use of the alumina flakes as a substrate for effect pigments and in organic dyes.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 12, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Ryuta Suzuki, Gerhard Pfaff, Sabine Schoen, Noriyuki Matsuda, Katsuhisa Nitta
  • Patent number: 10651389
    Abstract: The present invention relates to a compound of a formula (I), in which an electron-deficient group and an arylamino group are connected to one another via an intermediate group. The compound of the formula (I) is suitable as functional material in electronic devices.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 12, 2020
    Assignee: Merck Patent GmbH
    Inventors: Anja Jatsch, Christof Pflumm, Thomas Eberle, Amir Hossain Parham, Jonas Valentin Kroeber, Philipp Stoessel, Joachim Kaiser
  • Patent number: 10651388
    Abstract: The present invention relates to compositions comprising at least one polymer which contains triarylamine repeating units, and at least one metal complex, to methods for the production thereof, and the use thereof in electronic devices, especially in organic electroluminescent devices, so-called OLEDs (OLED=Organic Light Emitting Diode). The present invention also relates to organic electroluminescent devices which contain said compositions.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 12, 2020
    Assignee: Merck Patent GmbH
    Inventors: Katja Maria Scheible, Fabrice Eckes, Holger Heil, Henning Seim
  • Patent number: 10647771
    Abstract: The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jennifer H. Yearley, Linda Liang, Michael Eric Bigler, Christopher John Gibson
  • Publication number: 20200140411
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: October 31, 2019
    Publication date: May 7, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
  • Publication number: 20200144505
    Abstract: The present application relates to a blue light-emitting organic electroluminescent device (OLED) having an anode, a cathode, at least one blue light-emitting layer and at least one hole-transport layer, wherein the at least one blue light-emitting layer comprises an elongated bis-indenofluorene derivative as a main component and wherein the at least one hole-transport layer comprises a polymer with non-conjugated units as a main component as well as to a method for producing the organic electroluminescent device.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 7, 2020
    Applicant: Merck Patent GmbH
    Inventors: Katja Scheible, Beate Burkhart, Nils Koenen, Lara-Isabel Rodriguez, Sebastian Meyer, Rouven Linge, Miriam Engel, Aaron Lackner, Holger Heil
  • Publication number: 20200140445
    Abstract: The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: October 31, 2019
    Publication date: May 7, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok ARASAPPAN, Jason M. COX, John S. DEBENHAM, Zhuyan GUO, Jiafang HE, Zahid HUSSAIN, Zhong LAI, Derun LI, Dongfang MENG, Subharekha RAGHAVAN, Sriram TYAGARAJAN
  • Publication number: 20200139284
    Abstract: A filter housing assembly includes a base plate, an adapter block, and a shroud. The base plate may be permanently installed in a fluid-conveying system of conduits. A filter member is secured to a filter-receiving formation such as a pipe nipple extending from the adapter block and the shroud is secured to the adapter block to cover and seal the filter member. The adapter block is releasably secured to the base plate. The arrangement facilitates insertion and removal of the filter housing assembly into and out of the fluid-conveying system of conduits by converting multiple junction points into a single junction point, at which a subassembly consisting of just the shroud and the adapter block are connected into the system.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 7, 2020
    Applicant: Laboratories Merck Sharp & Dohme-Chibret
    Inventors: Bertrand Pessaud, Michael Meyer
  • Publication number: 20200139046
    Abstract: A reloadable auto injector includes a syringe with a needle movably positioned in a housing between a first position with the needle inside the housing and a second position with the needle protruding outside the housing. A plunger rod advances in the syringe for delivering a dose of medicament. A plunger rod tube having deflectable locking members interacts with a plunger rod stop to lock the plunger rod. A syringe driver moves the syringe from the first position to the second position. The syringe driver advances the plunger rod tube with the plunger rod to the second position. A plunger rod driver advances the plunger rod in the syringe for delivering a dose of medicament upon unlocking each of the deflectable locking members. A reload mechanism retracts the syringe from the second position to the first position and reloads for repeated activation of the syringe driver.
    Type: Application
    Filed: May 16, 2018
    Publication date: May 7, 2020
    Applicant: MERCK PATENT GMBH
    Inventor: Peter Blaabjerg JACOBSEN
  • Publication number: 20200141561
    Abstract: The present invention relates to a manufacturing method for a wavelength converting component which is prepared from a dispersion containing a crosslinkable ceramizable polymer material having a silazane repeating unit and at least one wavelength converting material. There are further provided wavelength converting components which can be used for converting blue, violet and/or UV light into light with a longer wavelength. There is also provided a light source and a lighting unit comprising said wavelength converting components.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 7, 2020
    Applicant: Merck Patent GmbH
    Inventors: Ralf GROTTENMUELLER, Abraham CASAS GARCIA-MINGUILLAN, Fumio KITA, Andreas BENKER, Ingo KOEHLER
  • Patent number: 10640658
    Abstract: The present invention relates to dielectric coatings and articles having high, but precisely defined specific surface resistances.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: May 5, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Reinhold Rueger, Matthias Kuntz
  • Patent number: 10640520
    Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 5, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Oliver Schadt, Philipp Haselmayer, Michael Busch
  • Patent number: 10639247
    Abstract: Disclosed are pigment mixtures containing at least two components, where component A contains bismuth oxychloride (BiOCl) or boron nitride (BN) and component B contains synthetic flakes treated with at least one metal soap or mineral flakes treated with at least one metal soap and to the use thereof especially in cosmetic formulations.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: May 5, 2020
    Assignee: Merck Patent Gesellschaft
    Inventors: Mark Tellefsen, Qinyun Peng
  • Patent number: 10644246
    Abstract: The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 5, 2020
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Philipp Stoessel, Thomas Eberle, Anja Jatsch, Jonas Valentin Kroeber, Tobias Grossmann, Christof Pflumm
  • Patent number: 10639353
    Abstract: Provided are methods of producing mono- and di-pegylated IL-10.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: May 5, 2020
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • Patent number: 10642104
    Abstract: The present invention relates to a method of controlling the pretilt angle in liquid crystal (LC) displays of the polymer sustained alignment (PSA) type, to a method of manufacturing a PSA display with different pretilt angles at the two substrates, and to PSA displays made by this method.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: May 5, 2020
    Assignee: Merck Patent GmbH
    Inventors: Eun-Kyu Lee, Hyun-Jin Yoon, In-Young Cho, Yong-Jun Ji
  • Patent number: 10640559
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 5, 2020
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Patent number: 10643058
    Abstract: The present invention is directed to a method for detection of microbial colonies on a surface, comprising the steps of obtaining one or a plurality of digital images I0, I1, I2, I3, I4 of the surface, said digital images I0, I1, I2, I3, I4 being represented by at least two-dimensional matrices of pixel values, calculating a statistical noise distribution based on at least one of the digital images I0, applying the statistical noise distribution calculated in the calculation step to the one or the plurality of digital images I0, I1, I2, I3, I4, and detecting an object of interest as a candidate for a microbial colony based on deviation of pixel values from the noise distribution.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 5, 2020
    Assignees: MERCK PATENT GMBH, UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Marine Bouthillon, Luc Felden, Ola Ahmad, Christophe Collet